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Abstract (200 words)
This systematic review evaluates the efficacy, safety and economic impact of dupilumab 
compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD).
Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic 
evaluations. Critical and important AD-related outcomes were considered. The risk of bias and 
the certainty of the evidence were assessed using GRADE.
Seven RCTs including 1845 subjects > 12 years treated with dupilumab 16 to 52 weeks were 
evaluated. For adults there is high certainty that dupilumab decreases SCORAD (MD -30,72; 
95%CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95%CI 2.45 to 3.89), pruritus (RR 2.96; 
95%CI 2.37 to 3.70), rescue medication (RR 3.46; 95%CI 2.79 to 4.30), sleep disturbance (MD -
7.29; 95%CI -8.23 to -6.35), anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves 
quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. 
Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for 
dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 
28,500 £ (low certainty) to 124,541 US$ (moderate certainty). More data on long term safety are 
needed both for children and adults, together with more efficacy data in the paediatric population.
Registration: PROSPERO (CRD42020153645). 
Abbreviations
AD = atopic dermatitis
AE = adverse events 
CDLQI = Children’s Dermatology Life Quality Index
CHEC = Consensus health economic criteria
CI = confidence interval
DLQI = Dermatology Life Quality Index
EAACI = European Academy of Allergy and Clinical Immunology
EASI = Eczema Area and Severity Index 
EMA = European Medicine Agency
FDA = Food and Drug administration
GDG = Guideline Development Group
GISS = Global Individual Sign Score
GRADE = Grading of Recommendations Assessment, Development and Evaluation
HAD-A = Hospital Anxiety and Depression Scale of anxiety
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ICER = Incremental cost-effectiveness ratio
Ig = immunoglobulin
IGA = Investigator´s Global Assessment 
IL = interleukin
IRR = incidence rate ratio
MD = mean difference
MID = minimal important difference
NRS = numerical rating scale 
OCS = oral corticosteroids
POEM = Patient-Oriented Eczema Measure
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
QALY = Quality adjusted life-years
QoL = quality of life
RCT = randomised controlled trial
ROB = risk of bias 
SOC = standard of care
RR= rate ratio
SC= subcutaneous
SR = systematic review
T2 = type 2
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory and relapsing disease characterised by dry and 
scale skin, eczematous lesions and intense itching that might turn chronic. AD displays a highly 
complex pathophysiology and heterogeneous phenotypes, which are illustrated by different 
features such as age of disease onset, variable response to triggers, spectrum of severity, barrier 
defect, potential of IgE autoreactivity and comorbidities (asthma, rhinitis, food allergy and 
infections) (1,2,3,4,5,6). Similar to asthma, AD research is developing and shaping precision 
medicine approaches aiming towards a biomarker based molecular taxonomy (7,8,9,10).
IL-4 and IL-13 are key cytokines in driving the initiation and chronicity of type 2 (T2) inflammation, 
a dominant inflammatory pathway in AD (11,12). Dupilumab is a fully human anti-IL-4 receptor α 
(IL-4Rα) monoclonal antibody that blocks both IL-4- and IL-13-mediated signalling pathways 
(13,14). The European Medical Agency (EMA) recommends dupilumab for moderate-to-severe 
AD in adult and adolescents (12 years and older) patients who are candidates for systemic 
therapy (15). The United States Food and Drug Administration (FDA) recommends dupilumab for 
patients aged 6 years and older with moderate-to-severe AD whose disease is not adequately 
controlled with topical prescription therapies or when those therapies are not advisable (16).
The European Academy of Allergy and Clinical Immunology (EAACI) is developing clinical 
practice guidelines for the use of biologicals in patients with uncontrolled moderate-to-severe AD. 
To inform key clinical recommendations, a systematic review (SR) evaluated the effectiveness 
and safety of dupilumab for patients with uncontrolled moderate-to-severe AD.
Methods
Guidelines Development Group
The EAACI Atopic dermatitis Voting Panel and Steering Committee included clinicians and 
researchers with different backgrounds (the complete list of experts is available from the EAACI 
website) who voluntarily participate in the development of the EAACI biologicals guideline. They 
are referred to as the Guidelines Development Group (GDG).
Structured question and outcome prioritisation
The GDG framed the clinical question as “Is the treatment with dupilumab efficacious and safe for 
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was defined as patients (≥12 years or older) with confirmed diagnosis of moderate-to-severe AD. 
Moderate-to-severe disease was defined as an Investigator´s Global Assessment (IGA) score of 
three or higher at baseline or an Eczema Area and Severity Index (EASI) score of 12 or higher at 
baseline. AD related outcomes were prioritised by the GDG group using a 1 to 9 scale (7 to 9 
critical; 4 to 6 important; 1 to 3 of limited importance), as suggested by the GRADE approach 
(table 2). The critical outcomes were SCORAD 75; EASI 50 or 75; pruritus and safety (drug-
related adverse events (AE) and drug-related serious AE (SAE)). The important outcomes were 
IGA, resource utilisation, rescue medication use, pain, sleep disturbance, symptoms of anxiety 
and depression, and Quality of life (QoL) (tables 1 and 2). The GDG also framed a cost-
effectiveness question to assess the economic impact of dupilumab versus standard of care or 
the best standard of care. The selected outcomes of interest were costs, resource use, and the 
incremental cost-effectiveness ratios (ICERs) per quality adjusted life-years (QALY).
Data source and searches 
Electronic algorithms in combination with controlled vocabulary and search terms were used to 
identify relevant randomised controlled trials (RCTs) and economic evaluations in: i) MEDLINE 
(via PubMed, February 2020); ii) Cochrane Controlled Trials Register (via The Cochrane Library, 
February 2020), and; iii) EMBASE (via Ovid, February 2020). Search algorithms were adapted to 
the requirements of each database, and validated filters were used to retrieve appropriate 
designs (tables S1 and S2). Additional studies provided by the GDG and previous SR were also 
evaluated (figure 1A and 1B). 
Eligibility criteria and selection of studies
The SR included RCTs comparing dupilumab versus placebo added to usual care/standard of 
care in patient with moderate-to-severe AD, and reporting one of the outcomes of interest as 
formulated by the GDG (figure 1 A and B). The SR excluded studies with dose or route not 
approved by the EMA or FDA, papers published as abstract or conference communications or not 
published in English. After initial calibration two reviewers independently screened the search 
results based on the title and abstract followed by independent assessment of the eligibility based 
on the full text. In case of disagreement a third reviewer was consulted. References were 
managed with Endnote version X9 software (Thomson Reuters, New York, USA).
Data extraction and risk of bias assessment
One reviewer independently extracted the main characteristics of eligible studies (study design, 









This article is protected by copyright. All rights reserved
checked for accuracy. If needed, authors of included studies were contacted to provide additional 
data. The Cochrane Risk of Bias tool for randomised trials was used to assess the risk of bias 
(ROB) of the included studies (15). The ROB was judged as low, high or unclear for each domain: 
random sequence generation, allocation concealment, blinding of participants and personnel, 
blinding for outcome assessment, incomplete outcome data, and selective reporting (figure S1) 
(16,17,18).
For the health economics analysis, two reviewers extracted the main characteristics of included 
studies (type of economic evaluation, perspective, time horizon, discounting, sources of 
information, model type), relevant outcomes (costs, ICERs, sensitivity analyses results), sources 
of funding, and conflict of interest. Methodological limitations of the economic evaluations were 
evaluated by two reviewers using the consensus on health economics criteria checklist (CHEC) 
(19). Transferability to the European context was assessed using the European Network of 
Health Economic Evaluation Databases (EURONHEED) checklist (20,21).
Data synthesis and analysis
The main results of the SR are described narratively and tabulated as summary of findings. Data 
were pooled and meta-analysed using Review Manager (Review Manager V.5.3, Cochrane 
Collaboration, Oxford, UK) using the random effects model approach. For binary outcomes 
pooled relative risk ratios and rate ratios (RRs) were calculated. For continuous outcomes mean 
differences (MDs) with 95% confidence intervals (CI), were used. If mean or standard deviations 
(SD), or changes of mean and SDs from baseline were not reported, standard errors (SE), CI, or 
the correlation coefficient were used. Where multiple arms were compared to a common placebo 
arm, SE were adjusted to avoid the unit of analysis error (22).
The magnitude of heterogeneity between the included studies was calculated using the Higgings’ 
I2 statistic interpreted according to the Cochrane Handbook guidelines (23). To account for 
clinical heterogeneity, subgroup analysis was predefined if possible by different doses of 
dupilumab, age and ROB. The median estimate reported in the control arms was used as 
baseline risk to estimate absolute effects. For the economic evidence, results are summarized 
narratively and tabulated, including the cost, incremental effectiveness, ICERs and the degree of 
uncertainty. 
Certainty of evidence
The certainty (quality) of the evidence of efficacy, safety and economic impact was rated for each 
outcome as high, moderate, low or very low, following the GRADE approach and the standard 
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(24,25). For the evaluation of imprecision for each outcome the following thresholds for the 
minimal important difference (MID) were considered when available: 8.7 points for Scoring Atopic 
Dermatitis (SCORAD) (26,27); 6.6 points for Eczema Area and Severity Index (EASI) (27,28); 4 
points for Patient-Oriented Eczema Measure (POEM) (27,29);  4 points for the Dermatology Life 
Quality Index (DLQI) (30); 6 points for Children’s DLQI (CDLQI) (31); 3 points for numerical rating 
scale (NRS) for adults (32,33) and 4 points for adolescents (31); 8 points or less for the Hospital 
Anxiety and Depression Scale of anxiety (HAD-A) or depression (HADS-D) (34). 
Results
Results are presented following the GRADE informative statements (35).
The systematic search retrieved 4377 citations. After excluding duplicates and screening the title 
and abstract, 29 full text papers were retrieved for the evaluation of dupilumab’s efficacy and 
safety (figure 1A). Twenty-two studies were excluded due to lack of abstract, dose not approved 
by the regulatory authorities, and duplicate data. Nine additional articles were suggested by the 
GDG group but excluded due to dose not approved by the regulatory authorities, non-randomised 
double-blind study design, not reporting outcomes of interests, or duplicate data (Table S3). The 
SR for the efficacy and safety included seven RCTs (36, 37, 38, 39, 40, 41) (figure 1A). For the 
economic evidence, after screening 1552 hits, five studies were considered suitable for inclusion 
(51,52, 53, 54,55) (figure 1B).
Characteristic of included studies
The main characteristics of the studies included are detailed in Tables S4 and S5. The RCTs 
included in the SR evaluated 1678 adults and 167 adolescents with moderate-to-severe AD 
inadequately controlled by topical treatment. Follow-up under treatment ranged from 16 weeks 
(36,37,39, 40) to one year (38). One RCT recruited responders from SOLO trials and continued 
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Evidence of efficacy and safety 
The summary of findings and certainty of evidence per outcome are reported in Tables 3, 4, 5A 
and 5B.
SCORAD index 
Six RCTs included in the SR reported the percentage change from baseline in SCORAD index 
assessed at 16 weeks (36,37,39,40). Dupilumab reduced with high certainty of evidence the 
SCORAD value compared to standard of care in adults (MD -30,72%; 95% CI -34,65% to -
26,79%) and in adolescents (MD -34%; 95% CI -43.74% to -24.26%). One study reported on 
SCORAD reduction at 52 weeks (MD -32.1%; 95%CI, -39.27% to -24.93%) (38). Another RCT 
reported a small to no effect in the 36 weeks follow-up of SOLO trials (MD + 0.97%; 95%CI 
+0.69% to +1.25%) (41).
Eczema Area and Severity Index (EASI)
Six RCTs reported the proportion of patients achieving 75% improvement (EASI-75) at 16 weeks 
(36,37,38,39,40). Dupilumab treatment in adult patients with standard of care versus placebo 
resulted with high certainty in a significant increase in the number of patients who achieved EASI-
75 (RR 3.09; 95%CI 2.45 to 3.89; absolute increase +383 per 1000 patients, 95%CI from +266 to 
+530). Similar results were reported for adolescents (RR 5.03; 95%CI 2.37 to 10.71; absolute 
increase +332 per 1000 patients, 95%CI from +113 to +800). All six RCTs also reported the 
proportion of patients with 50% improvement (EASI-50) at 16 weeks. Their results showed a 
significant increase in EASI-50 responders compared to standard of care in adults (RR 2.43; 
95%CI 2.04 to 2.89) and adolescents (RR 4.71; 95%CI 2.64 to 8.40). A comparable increase was 
reported at 52 weeks for EASI-75 (RR 3.02; 95%CI 2.29 to 3.98) and EASI-50 (RR 2.63; 95% CI 
2.12 to 3.26) in one RCT (38). The impact on EASI was maintained during the 36 weeks of follow-
up in the SOLO trials (EASI-75 RR 2.36, 95%CI 1.66 to 3.34; EASI-50 RR 1.85, 95%CI 1.39 to 
2.44) (41).
Pruritus 
Six RCTs measured the effect of dupilumab treatment on pruritus through the proportion of 
patients with an improvement of ≥ 4 points in the numerical rating scale (NRS) at 16 weeks 
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for adults (RR 2.96; 95% CI; 2.37 to 3.70; absolute effect + 311 per 1.000 patients, 95%CI from 
+217 to +429) and for adolescents (RR 7.68; 95% CI; 2.83 to 20.84; absolute effect +318 per 
1.000 patients, 95%CI from + 87 to +945). One study (38) reported a significant reduction of 
pruritus at 24 weeks (RR 3.98; 95%CI 2.71 to 5.84) and at 52 weeks (RR 3.36; 95% CI 2.45 to 
4.60), and the effect was maintained during the 36 weeks follow-up (SOLO trials; RR 3.83, 95%CI 
2.10 to 6.97) (41). The effect on pruritus was also quantified by percent change from baseline of 
peak pruritus NRS score (36,37,38,39,40,41). The pooled analysis illustrated a significant 
dupilumab-induced NRS score improvement at 16 weeks for adults (MD -28.04%; 95% CI -
32.65% to -23.43%) and for adolescents (MD -28.90%; 95% CI -39.34% to -18.46%). In the 36 
weeks follow-up period of SOLO trials no improvement in the NRS score was reported (MD -
0.53%, 95%CI -0.79 to -0.26) (41).
Safety
Dupilumab may increase (low certainty of evidence) treatment-related AE at 16 weeks (RR 1.29; 
95%CI 0.62 to 2.72; absolute increase +118 per 1000 patients; 95% CI from -155 to +702) 
(36,39). Most of the treatment-related AEs were eye inflammation (conjunctivitis). Dupilumab was 
safe in adolescents: the analysis of the potential increase in dupilumab-related AE showed little to 
no difference with moderate certainty (RR 1.04; 95%CI 0.85 to 1.26; absolute increase +28 per 
1000 patients; 95%CI from - 104 to + 180) (40).  Dupilumab-related severe AE were reduced for 
adults (RR 0.50; 95%CI 0.09 to 2.70; absolute increase -12 per 1.000 patients; 95%CI from -22 to 
+40) and for adolescents (RR 0.35; 95%CI 0.01 to 8.36, absolute increase -8 per 1000 patients; 
95%CI from -12 to +87). The evidence is very uncertain both for adults and adolescents. The 
SOLO trials reported decreased treatment-related AE (RR 0.86, 95%CI 0.75 to 1.00) and 
increase treatment-related severe AE (RR 2.95, 95%CI 0.36 to 24.07) (41). 
Investigator’s Global Assessment (IGA) score 
Four RCTs defined the primary outcome as the proportion of patients who achieved both a score 
of 0/1 (0=clear or 1=almost clear) on the investigator’s global assessment and a reduction of  2 
points from baseline at 16 weeks (37,38,39). Dupilumab significantly increased the proportion of 
patients’ achieving both end-points with high certainty of evidence (RR 3.46; 95% CI 2.79 to 4.3; 
absolute effect + 270 per 1.000 patients, 95%CI from + 197 to +363). Two other RCTs (36,40) 
defined the primary outcome as the proportion of patients with an IGA response 0/1 at 16 weeks, 
showing a significant effect both for adults (RR 18.11; 95%CI 2.50 to 131.17) and for adolescents 
(RR 10.37; 95%CI 2.50 to 42.95). The effect was maintained in the 36 weeks follow-up of SOLO 
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Use of rescue medication
Five RCTs reported on this outcome at 16 weeks (37,38,39,40). The pooled analysis showed that 
dupilumab significantly reduces with high certainty of evidence the proportion of the patients who 
use any rescue medication, both for adults (RR 0.36; 95%CI 0.28 to 0.46, absolute effect - 270 
per 1.000 patients, 95%CI from - 304 to - 228 fewer) and for adolescents (RR 0.35; 95%CI 0.22 
to 0.56, absolute effect - 382 per 1.000 patients, 95%CI from -45 to -259). The effect was 
maintained in the 36 weeks follow-up of SOLO trials (MD 0.69, 95%CI 0.43 to 0.96) (41).
Pain
One RCT included in the SR measured the effect of dupilumab on pain trough the proportion of 
patients with no complains in the item 4 (pain/discomfort) of the EQ-5D questionnaire. For the 
adult population, dupilumab significantly reduced the number of patients with pain and discomfort, 
with high certainty of evidence (RR 1.89; 95%CI 1.44 to 2.49; absolute effect + 330 more per 
1,000 patients; 95%CI +163 to +552) (39). 
Sleep disturbance
Six RCTs measured the impact on sleep disturbance with the change in the POEM score at 16 
weeks. Dupilumab significantly reduced the severity of sleep disturbance (MID=4) with high 
certainty of evidence in adults (MD -7.29; 95%CI -8.23 to -6.35) (36,37,38,39) and with moderate 
certainty of evidence in adolescents (MD -6.30; 95%CI -8.81 to -3.79) (40). One RCT evaluated 
POEM at 52 weeks and showed a similar effect (MD is -8.4; 95%CI -10.12 to -6.68) (38).  In the 
36 weeks follow-up of SOLO trials, an opposite effect was reported (MD 0.96, 95%CI 0.68 to 
1.23) (41). 
Anxiety and depression
Six RCTs reported this outcome considering the change from baseline of HADS at 16 weeks. The 
pooled analysis showed that dupilumab reduces symptoms of anxiety and depression with high 
certainty of evidence in adults (MD -3.08; 95%CI -4.41 to -1.75) and with moderate certainty in 
adolescents (MD -1.30; 95%CI -3.38 to +0.78). In the 36 weeks follow-up of SOLO trials an 
opposite effect was reported (MD 0.31, 95%CI 0.04 to 0.57) (41). Two RCTs (38,39)) evaluated 
this outcome as the proportion of the patients with no clinically relevant symptoms of anxiety and 
depression at 16 weeks (RR 1.78; 95% CI 1.35 to 2.33) and one of the two RCTs reported a 
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Quality of life
QoL outcome was measured by DLQI for adults (36,37,38,39) and by CDLQI for adolescents 
(40). The pooled analysis showed a significant improvement (above the MID of 4 and 6, 
respectively) in the QoL with high certainty of evidence both for adults (MD -4.80; 95%CI -5.55 to 
-4.06) and for adolescents (MD -13.60; 95%CI -15.13 to -12.07). Four RCTs reported on the QoL 
in adults with AD measured by Global Individual Sign Score (GISS) (37, 38, 39) and showed that 
dupilumab improves QoL (MD -26.39%; 95% CI -30.62% to -22.15%). Dupilumab improves QoL 
at 52 weeks: DLQI (MD -4.40; 95%CI -5.7 to -3.05) and GISS (MD -29.10%; 95%CI from -36.67% 
to -21.53%) (38). In the 36 weeks follow-up of SOLO trials, deterioration of QoL was reported 
(MD 0.74, 95%CI 0.47 to 1.01) (41).
Cost-effectiveness 
Four Markov model-based evaluations assessing dupilumab versus standard of care (42, 43, 44, 
45), and one comparing dupilumab with best supportive care (education, psychological support, 
emollients, topical corticosteroids, bandages, and hospitalisation) (46) were included into the 
analysis. Three evaluations were conducted from the perspective of the United States’ healthcare 
system (42,43,44), one was performed in Canada (45), and one in the UK (46). The annual 
dupilumab related cost per patient was highest in the US studies (up to 37,000 US$) followed by 
the Canadian study (25,918 C$) and by the UK study (16,500 £). The costs of medication were 
lower in the UK (632.45 £) compared with Canada (959.94 C$) and the US (up to 1,300.00 US$). 
The ICER per QALY of dupilumab added to the standard of care was 100,000 US$ or higher 
(42,43,44,45). The sensitivity analyses showed variations in the ICER from 78,300 US$ in 
patients with severe AD to 159,988 US$ in those with moderate AD. The Canadian Agency for 
Drugs and Technologies in Health (CADTH) undertook an analysis for patients, refractory to, or 
ineligible for systemic immunosuppressant therapies obtaining an ICER of 133,877 C$, which is 
within the range of ICERs found by the US studies (Table 5A). The National Institute for Clinical 
Excellence undertook an analysis of dupilumab as fifth-line treatment, after topical therapies and 
systemic immunosuppressant have failed. In this scenario the ICER value was 28,495.00 £, 
which is lower than the previous ones (Table 5B). 
There was moderate certainty of the evidence for the studies assessing the economic impact of 
dupilumab versus standard of care due to concerns for indirectness, as unitary costs were 
provided by studies performed in the US (42,43,44) and Canada (45). These results may not 
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dupilumab with the best supportive care due to serious concerns for indirectness in the 
comparator (including therapies beyond topical treatment) and the population (patients receiving 
dupilumab as fifth-line treatment, after systemic immunosuppressant therapies). 
Discussion
Main findings
The current systematic review showed that dupilumab as add-on treatment for moderate-to-
severe AD in adults and adolescents significantly reduces short-term (16 weeks) AD symptoms, 
severity, use of rescue medication, and improves quality of life. For adults there is good evidence 
for long-term efficacy (52 weeks). Dupilumab may increase short-term drug-related AE. The 
evidence for severe drug-related AE is very uncertain. All RCTs were mainly powered for efficacy 
and less powered to show rare adverse events which are now frequently reported in the post-
marketing literature.
The ICER per QALY of dupilumab versus standard of care was above 100,000 US$, considered 
as threshold for the willingness to pay in several high-income countries (47). Drug-related costs 
were the key driver of this ICER in all studies. The CADTH analysis recommended a price 
reduction of at least 54% to obtain an ICER value below the threshold of 50,000 C$. Another 
important factor impacting the ICER was the profile of patients included in the analysis. In the 
NICE analysis, dupilumab plus topical corticosteroids was found to be cost-effective for treating 
atopic dermatitis not responding to other systemic therapies, such as ciclosporin, methotrexate, 
azathioprine and mycophenolate mofetil, or when these options were contraindicated or not 
tolerate. Dupilumab improved their quality of life compared to best supportive care and it was key 
for generating an acceptable ICER value of 28,500 £, which is in line with previous authors 
suggesting that the high cost of dupilumab for severe AD is offset by the quality of life 
improvement (48).
The main reason to downgrade the certainty of the evidence for the efficacy and safety outcomes 
was imprecision and inconsistency, and the indirectness for economic data. All the studies were 
funded by the same company and reported positive effects, which might raise concerns for a 
potential sponsorship bias. Moderate certainty of evidence for economic impact was available 
from three studies with low risk of bias but with important indirectness. All economic analyses 
were performed in high-income countries in line with their health system perspectives, thus their 
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Current report in the context of previous research
This SR is the most up to date review on the effectiveness, safety and economic impact on 
dupilumab in AD. Similar to previous SRs the current analysis reinforces the short-term (16 
weeks) efficacy of dupilumab in improving SCORAD, EASI, IGA, pruritus, and quality of life 
(49,50,51). In addition, the current SR provides evidence for long-term (52 weeks) benefit in 
adults. 
According to the current SR in adults with AD dupilumab may increase treatment-related AE 
(conjunctivitis/ injection side reactions/ eosinophilia), although there is low certainty of evidence. 
The evidence for treatment-related severe AE is very uncertain both for adults and for 
adolescents. The pooled analysis from laboratory findings from three randomized, double-
blinded, placebo-controlled phase 3 trials showed no clinically important changes in routine 
laboratory parameters that could be attributed to dupilumab, thus supporting the use of dupilumab 
as a systemic treatment for moderate-to-severe AD that does not require laboratory monitoring 
(52).
The use of variable outcomes limited the conclusions of previous SRs (50). For the current SR 
the GDG predefined and prioritised AD-related outcomes. 
Previous SRs included all dupilumab doses for AD, while the current SR only included FDA/EMA 
approved doses, which are more informative for issuing recommendations for clinical practice. 
Although a recent SR included the efficacy of dupilumab for adolescent AD population (51), they 
did not report separately for this population.
Furthermore, the current SR followed the GRADE approach for rating of the certainty of evidence. 
In contrast to previous SRs (49,50) that assessed only the risk of bias, the current SR considered 
all relevant aspects related with the certainty of evidence like heterogeneity, indirectness or 
imprecision of the results. 
Finally, an evaluation of cost-effectiveness was included, thus providing additional support for the 
GDG in formulating recommendations. 
Limitations and strengths
The current SR has several strengths. First, a comprehensive systematic search was conducted 
on three databases, checking for efficacy, safety and cost-effectiveness. Second, rigorous 
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certainty of the evidence. The outcomes included were prioritised beforehand and the minimal 
important difference was considered when available for all AD-related outcomes. 
Optimal presentation of results into tabulated format (summary of findings) is provided aiming to 
improve communication to patients, clinicians, and other stakeholders.
There are some limitations as well. Only studies published in English were included. However, 
the studies included in previous systematic reviews were thoroughly evaluated and additional 
studies were suggested by the GDG, which decreases the possibility of missing studies. No 
observational studies were included, which could inform better on outcomes with low quality of 
evidence (i.e, serious adverse events). However, they will be considered when formulating 
recommendations. A ‘de novo’ economic analysis was not conducted; however, a rigorous and 
explicit critical appraisal and transferability assessment of cost-effectiveness data is provided.
Conclusion
Dupilumab demonstrated a significant short-term benefit for the adults and adolescents with 
uncontrolled moderate-to-severe atopic dermatitis, by improving symptoms and disease severity, 
reducing the use of rescue medications and improving the quality of life. For adults there is 
evidence for long-term benefit.  Thresholds for cost-effectiveness are probably acceptable for 
some high-income countries, however dupilumab might not be equally cost-effective in countries 
with limited resources. 
Although short term safety data showed no visible increase of AE, more accurate AE reporting is 
warranted in RCTs for both adult and adolescent population, combined with long-term safety 
evaluation using observational and effectiveness studies and registries. There are several 
ongoing open-label studies (53,54) and registries (55) evaluating the long-term safety and 
efficacy of dupilumab in atopic dermatitis that are likely to be informative in formulating 
recommendations.
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Table 1. Structured clinical question  
Population Intervention Comparison Outcomes 
Atopic dermatitis 
patients (≥12 years or 
older) with confirmed 
diagnosis of moderate to 
severe atopic dermatitis. 
Adults/Adolescent with weight at 
least 60 kg: Initial dose of 600 mg 
(two 300 mg injections) followed 
by 300 mg given every other week; 
 
Adolescent with weight less than 
60 kg: initial dose of 400 mg (two 
200 mg injection) followed by 200 






• EASI 50 or 75 
• Pruritus – measured by numerical 
rating scale (NRS), peak score on 
NRS, and the percent body surface 
area affected 
• Safety (adverse events)* 
Important:  
• Investigator’s Global Assessment 
(IGA) 
• Rescue medication use 
• Pain 
• Sleep disturbance – measured by 
the Patient-Oriented Eczema 
Measure (POEM) 
• Symptoms of anxiety and 
depression – measured by the 
Hospital Anxiety and Depression 
Scale (HADS) 
• Quality of life (QOL) - measured by 
Dermatology Life Quality Index 
(DLQI) and Global Individual Signs 
Score (GISS) for adults, or C 
*Only drug related adverse events and severe adverse events were considered 
 
Table 2: GRADE scoring of AD related outcomes 
 
Outcome Importance 
SCORAD 75; EASI 50 or 75;  
Pruritus 
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IGA, resource utilization, rescue medication use, pain, sleep 
disturbance, symptoms of anxiety and depression, and Quality of 
life (QOL) 
Important (4-6) 
Cutaneous microbial community structure, skin barrier biology, 
and circulating T-cell profiles 
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Figure 1. The eligibility process using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) flowchart  







Records excluded by 
screening (n = 4348)  
• Not relevant to diseases 
of interest: 2774 
• Not relevant to Atopic 
dermatitis and 
dupilumab:758 
• Duplicate: 816 
Full-text articles assessed for 
eligibility  
(n =29) 
Excluded at full text level: 31 
• Abstract and comments: 6 
• Duplicated data: 13 
• Dose not approved by FDA: 8 
• Different study design: 2 
• No predefined outcome and 
subgroup: 2 
Studies included 
n = 7 



























Unique number of studies 
(n=1966) (EMBASE) 
Unique number of studies 
(n=1018) (MEDLINE) 
Unique number of studies 
(n=1393) (CENTRAL) 
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B. Studies evaluating the economic impact of dupilumab  
 
  
Records excluded by 
screening (n = 1549)  
• Not relevant to dupilumab 
for atopic dermatitis: 848 
• Duplicate: 701 
Full-text articles assessed for 
eligibility  
(n =3) 
Excluded at full text level: 1 
• Systematic review use as 
source of primary studies: 
1 
Studies included 




























Unique number of studies 
(n=1491) (EMBASE) 
Unique number of studies 
(n=57 ) (MEDLINE) 
Unique number of studies 
(n=4) (CENTRAL) 
Found from previous 
systematic reviews and 
provided by the GDG 
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Table 3. Summary of evidence for the outcomes of interest 
Adult atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care  
Population: Adults with uncontrolled atopic dermatitis  
Intervention: Dupilumab  














Anticipated absolute effects 
Risk with 






Assessed with least square (LS) mean % 









-  -  
MD - 30.72 %  





Assessed with proportion of patients 


















Assessed with improvement in peak score on 

















Treatment-related adverse events (AEs) 


















Treatment-related severe adverse events 
(SAE)  













per 1,000  
-12 per 1,000 
(-22 to +40) 
Rescue medication use 
Assessed with number of patients who 












422 per 1,000  
-270 per 
1,000 
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Table 3. Summary of evidence for the outcomes of interest 
Adult atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care  
Population: Adults with uncontrolled atopic dermatitis  
Intervention: Dupilumab  














Anticipated absolute effects 
Risk with 





Sleep disturbance - Patient-Oriented Eczema 
Measure (POEM) 


















Assessed with: Proportion of patients with 
no problem of the EQ-5D item 4 
(pain/discomfort)  
215 














Symptoms of anxiety and depression 
Hospital Anxiety and Depression Scale 
(HADS) (HADS) 








-  - 






Quality of life measured with Dermatology 
Life Quality Index (DLQI)  
Assessed with: LS mean change from 
baseline 









-  -  
MD - 4.8 
points  




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).  
 
AE= adverse events; CI: Confidence interval; LS = least square; MD: Mean difference; MID: minimal important difference 
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Table 3. Summary of evidence for the outcomes of interest 
Adult atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care  
Population: Adults with uncontrolled atopic dermatitis  
Intervention: Dupilumab  














Anticipated absolute effects 
Risk with 





GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderately confidence in the effect estimate: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate : the true effect may be substantially different from the estimate of the 
effect 
Very low certainty: Very limited confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect 
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2016.  
4. Blauvelt A, de Bruin-Weller M. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and 
concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, 
phase 3 trial. Lancet; 2017.  
5. Simpson EL, Gadkari A, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported 
outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe 
atopic dermatitis (AD). J Am Acad Dermatol; 2016.  
 
Explanations 
a. The MID for SCORAD is 8.7 points   
b. All Included studies were funded by industry. No industry-independent observational or randomized studies to support 
these results were found (sponsorship industry bias was assessed as other bias as part of the ROB tool). The panel 
members considered that there were no major concerns about potential publication/sponsorship bias  
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d. The I2 was 51% with no significant difference(p=0.08), and this was influenced by only one study with a low number of 
events.  
e. The MID for EASI is 6.6 points  
f. The clinically improvement cut off for NRS was considered 3 points  
g. The MID for POEM is 4 points  
h. Blauvelt 2017 also evaluated this outcome at 52 weeks (MD is -8.4; 95%CI -10.12 to -6.68).  
i. This outcome was also evaluated as the proportion of the patients with HADS-A and HADS-D scores <8, considered as 
the clinically relevant end point.  The RR was 1.78(95% CI 1.35 to 2.33was   
j. The MID for DLQI is 4 points   
k. Simpson,Gadkari 2016 evaluated the QoL by EQ-5D-3L, the MD (SE) is 14.4(3.3) in the dupilumab group and 2.4 (3.5) in 
the placebo group. Bruin-Weller 2017 evaluated EQ-5D item 4 (pain/discomfort), the proportion of the patients 
reporting “no problem” at week 16 is 75 (70.1%) in dupilumab group and 40 (37.0%) in the placebo group.  
l. Included studies also evaluated quality of life with Global Individual Signs Score (GISS) at 16 weeks (MD is -26.39%; 
95%CI -30.62 to -22.15%).  
m. Important unexplained heterogeneity (I
2
 = 88%, p=0.003).  
n. The effect may be harmful or beneficial.  
o. Downgraded three levels due to very few events reported. The effect can be harmful or beneficial. 
 
Table 4. Summary of evidence for the outcomes of interest 
Adolescents atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care 
Patient or population: Adolescent with uncontrolled atopic dermatitis 
Intervention: Dupilumab  
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Table 4. Summary of evidence for the outcomes of interest 
Adolescents atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care 
Patient or population: Adolescent with uncontrolled atopic dermatitis 
Intervention: Dupilumab  
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Treatment-related adverse events (AEs) 


















Treatment-related severe adverse events (SAE)  













12 per 1,000  
-8 per 1,000 
(-12 to +87)  
IGA  
Assessed with proportion of patients who 

















Rescue medication use 
Assessed with number of patients receiving any 

















Sleep disturbance - Patient-Oriented Eczema 
Measure  
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MD - 6.3 
points 
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Table 4. Summary of evidence for the outcomes of interest 
Adolescents atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care 
Patient or population: Adolescent with uncontrolled atopic dermatitis 
Intervention: Dupilumab  





















Symptoms of anxiety and depression Hospital 
Anxiety and Depression Scale (HADS)  















Quality of life measured by Children’s 
Dermatology Life Quality Index (CDLQI) 









-  -  
MD -13.6 
points  
(-15.13 to - 
12.07)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).  
 
AE= adverse events; CI: Confidence interval; LS = least square; MD: Mean difference; MID: minimal important difference 
RR: Risk ratio; SAE = serious adverse events 
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderately confidence in the effect estimate: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate : the true effect may be substantially different from the estimate of the 
effect 
Very low certainty: Very limited confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect 
References 
1. Simpson EL, Paller AS,Siegfried EC ,et al.. Efficacy and Safety of Dupilumab in Adolescents with Uncontrolled Moderate to 
Severe Atopic Dermatitis: a Phase 3 Randomized Clinical Trial. JAMA dermatology; 2019. 156(2):131-143. 
 
Explanations 
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b. Included studies were funded by industry. No industry-independent observational or randomized studies were identified 
to contrast the results. No industry-independent observational or randomized studies were found to support these results 
(sponsorship industry bias was assessed as other bias as part of the ROB tool). The panel members considered that there 
were no major concerns about potential publication/sponsorship bias 
c. The MID for EASI is 6.6 points  
d. The clinically improvement cut off for NRS was considered as 4   
e. The MID for POEM is 6 points  
f. The clinically relevant end point outcome was considered as the proportion of the patients with HADS-A and HADS-D 
scores <8   
g. The effect may be harmful or beneficial  
h. The MID for CDLQI is 6 points  
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Table 5 A: Summary of evidence for the economic impact of dupilumab in addition to standard care 
(emollients) vs. standard of care 













































*Incremental cost and effect due to the addition of dupilumab (not reported by the CADTH study). ICER: Incremental cost-
effectiveness ratio. QALY: Quality adjusted life years. USD$: US Dollar. 
Explanations 
a. Markov model studies with low risk of bias (CHEC score 13 or higher).  
b. The studies were performed in the USA and Canada. The results may not be applicable to other countries. 
c. The sensitivity analyses of the US studies showed variations in the ICER value from 78,300 USD$ in patients with 
severe AD and 159,988 USD$ in moderate AD. At a threshold of 150,000 USD$, the probability for dupilumab to be 
cost-effective was 77% or higher in all three studies. CADTH undertook a scenario analysis for patients who are 
refractory to or ineligible for systemic immunosuppressant therapies, which resulted in an ICER of $133,877 Canadian 
Dollars, that is included in the ICERs found by the US studies.  
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Adults. Dermatol Ther (Heidelb). 2017; 7(4): 493-505. 
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Table 5 B: Summary of evidence for the economical impact of Dupilumab in addition to topical corticoids (as 
fifth-line treatment, after systemic immunosuppressant therapies) vs. best supportive care (education, 
psychological support, emollients, topical corticosteroids, bandages and hospitalisation) 


















































*Incremental cost and effect due to the addition of dupilumab. ICER: Incremental cost-effectiveness ratio. QALY: Quality 
adjusted life years. £: British Pounds. 
Explanations 
a. Markov model study with low risk of bias (CHEC score 16.5).  
b. Very serious indirectness due to differences in the comparator and the population. First, the comparator was best 
supportive care (include education, psychological support, emollients, topical corticosteroids, bandages and 
hospitalisation), which is different to the standard care that included topical treatments. Second, the study was 
performed in the UK for patients that could receive dupilumab as fifth-line treatment, after systemic 
immunosuppressant therapies. The results may not be applicable to other populations. 
c. The sensitivity analysis that use a curve fit estimator of maintenance of response of 18.2%, 10.3%, 6.2% and 3.7% in 
the best supportive care arm showed an ICER of £27,410. 
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Table 1. Structured clinical question  
Population Intervention Comparison Outcomes 
Atopic dermatitis 
patients (≥12 years or 
older) with confirmed 
diagnosis of moderate to 
severe atopic dermatitis. 
Adults/Adolescent with weight at 
least 60 kg: Initial dose of 600 mg 
(two 300 mg injections) followed 
by 300 mg given every other week; 
 
Adolescent with weight less than 
60 kg: initial dose of 400 mg (two 
200 mg injection) followed by 200 






• EASI 50 or 75 
• Pruritus – measured by numerical 
rating scale (NRS), peak score on 
NRS, and the percent body surface 
area affected 
• Safety (adverse events)* 
Important:  
• Investigator’s Global Assessment 
(IGA) 
• Rescue medication use 
• Pain 
• Sleep disturbance – measured by 
the Patient-Oriented Eczema 
Measure (POEM) 
• Symptoms of anxiety and 
depression – measured by the 
Hospital Anxiety and Depression 
Scale (HADS) 
• Quality of life (QOL) - measured by 
Dermatology Life Quality Index 
(DLQI) and Global Individual Signs 
Score (GISS) for adults, or C 
*Only drug related adverse events and severe adverse events were considered 
 
Table 2: GRADE scoring of AD related outcomes 
 
Outcome Importance 
SCORAD 75; EASI 50 or 75;  
Pruritus 
Safety (adverse events) 
Critical (7-9) 
IGA, resource utilization, rescue medication use, pain, sleep 
disturbance, symptoms of anxiety and depression, and Quality of 
life (QOL) 
Important (4-6) 
Cutaneous microbial community structure, skin barrier biology, 
and circulating T-cell profiles 














Figure 1. The eligibility process using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) flowchart  







Records excluded by 
screening (n = 4348)  
• Not relevant to diseases 
of interest: 2774 
• Not relevant to Atopic 
dermatitis and 
dupilumab:758 
• Duplicate: 816 
Full-text articles assessed for 
eligibility  
(n =29) 
Excluded at full text level: 31 
• Abstract and comments: 6 
• Duplicated data: 13 
• Dose not approved by FDA: 8 
• Different study design: 2 
• No predefined outcome and 
subgroup: 2 
Studies included 
n = 7 
































Unique number of studies 
(n=1966) (EMBASE) 
Unique number of studies 
(n=1018) (MEDLINE) 
Unique number of studies 
(n=1393) (CENTRAL) 












B. Studies evaluating the economic impact of dupilumab  
 
  
Records excluded by 
screening (n = 1549)  
• Not relevant to dupilumab 
for atopic dermatitis: 848 
• Duplicate: 701 
Full-text articles assessed for 
eligibility  
(n =3) 
Excluded at full text level: 1 
• Systematic review use as 
source of primary studies: 
1 
Studies included 

































Unique number of studies 
(n=1491) (EMBASE) 
Unique number of studies 
(n=57 ) (MEDLINE) 
Unique number of studies 
(n=4) (CENTRAL) 
Found from previous 
systematic reviews and 
provided by the GDG 











Table 3. Summary of evidence for the outcomes of interest 
Adult atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care  
Population: Adults with uncontrolled atopic dermatitis  
Intervention: Dupilumab  














Anticipated absolute effects 
Risk with 






Assessed with least square (LS) mean % 









-  -  
MD - 30.72 %  
(-34.65 to - 
26.79) d 
EASI-75 
Assessed with proportion of patients 


















Assessed with improvement in peak score on 

















Treatment-related adverse events (AEs) 
Assessed with number of patients reporting 
AEs 
340 












Treatment-related severe adverse events 
(SAE)  
Assessed with number of patients reporting 
AAEs 
340 









per 1,000  -12 per 1,000 
(-22 to +40) 
Rescue medication use 
Assessed with number of patients who 












422 per 1,000  
-270 per 
1,000 
(-304 to -228)  
Sleep disturbance - Patient-Oriented Eczema 
Measure (POEM) 


















Assessed with: Proportion of patients with 
no problem of the EQ-5D item 4 
(pain/discomfort)  
215 














Symptoms of anxiety and depression 
Hospital Anxiety and Depression Scale 
(HADS) (HADS) 








-  - 














Table 3. Summary of evidence for the outcomes of interest 
Adult atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care  
Population: Adults with uncontrolled atopic dermatitis  
Intervention: Dupilumab  














Anticipated absolute effects 
Risk with 





Quality of life measured with Dermatology 
Life Quality Index (DLQI)  
Assessed with: LS mean change from 
baseline 









-  -  
MD - 4.8 
points  




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).  
 
AE= adverse events; CI: Confidence interval; LS = least square; MD: Mean difference; MID: minimal important difference 
RR: Risk ratio ; SAE = serious adverse events 
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderately confidence in the effect estimate: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate : the true effect may be substantially different from the estimate of the 
effect 
Very low certainty: Very limited confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect 
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Dermatitis. N Engl J Med; 2016.  
2. de Bruin-Weller M, Thaçi D, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic 
dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a 
placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol; 2018.  
3. Thaçi D, Simpson EL, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis 
inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet; 
2016.  
4. Blauvelt A, de Bruin-Weller M. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and 
concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, 
phase 3 trial. Lancet; 2017.  
5. Simpson EL, Gadkari A, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported 
outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe 
atopic dermatitis (AD). J Am Acad Dermatol; 2016.  
 
Explanations 
a. The MID for SCORAD is 8.7 points   
b. All Included studies were funded by industry. No industry-independent observational or randomized studies to support 
these results were found (sponsorship industry bias was assessed as other bias as part of the ROB tool). The panel 
members considered that there were no major concerns about potential publication/sponsorship bias  
c. Blauvelt 2017 evaluated this outcome at 52-week (MD is 32.1%; 95%CI, -39.27% to -24.93%).  
d. The I2 was 51% with no significant difference(p=0.08), and this was influenced by only one study with a low number of 
events.  
e. The MID for EASI is 6.6 points  
f. The clinically improvement cut off for NRS was considered 3 points  











h. Blauvelt 2017 also evaluated this outcome at 52 weeks (MD is -8.4; 95%CI -10.12 to -6.68).  
i. This outcome was also evaluated as the proportion of the patients with HADS-A and HADS-D scores <8, considered as 
the clinically relevant end point.  The RR was 1.78(95% CI 1.35 to 2.33was   
j. The MID for DLQI is 4 points   
k. Simpson,Gadkari 2016 evaluated the QoL by EQ-5D-3L, the MD (SE) is 14.4(3.3) in the dupilumab group and 2.4 (3.5) in 
the placebo group. Bruin-Weller 2017 evaluated EQ-5D item 4 (pain/discomfort), the proportion of the patients 
reporting “no problem” at week 16 is 75 (70.1%) in dupilumab group and 40 (37.0%) in the placebo group.  
l. Included studies also evaluated quality of life with Global Individual Signs Score (GISS) at 16 weeks (MD is -26.39%; 
95%CI -30.62 to -22.15%).  
m. Important unexplained heterogeneity (I2 = 88%, p=0.003).  
n. The effect may be harmful or beneficial.  
o. Downgraded three levels due to very few events reported. The effect can be harmful or beneficial. 
 
Table 4. Summary of evidence for the outcomes of interest 
Adolescents atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care 
Patient or population: Adolescent with uncontrolled atopic dermatitis 
Intervention: Dupilumab  






















Assessed with least square (LS) mean % change 
from baseline 
167 






-  -  





Assessed with proportion of patients achieving 
EASI-75 (%) 
167 















Assessed with improvement in peak score on 
NRS for pruritus ≥ 4 points 
166 














Treatment-related adverse events (AEs) 
Assessed with number of patients reporting 
AEs 
167 














Treatment-related severe adverse events (SAE)  
Assessed with number of patients reporting 
AAEs 
167 









12 per 1,000  -8 per 1,000 
(-12 to +87)  
IGA  
Assessed with proportion of patients who 
achieved 0/1 points 
167 
























Table 4. Summary of evidence for the outcomes of interest 
Adolescents atopic dermatitis population: Dupilumab efficacy and safety compared to standard of care 
Patient or population: Adolescent with uncontrolled atopic dermatitis 
Intervention: Dupilumab  





















Rescue medication use 
Assessed with number of patients receiving any 
rescue therapy  
167 














Sleep disturbance - Patient-Oriented Eczema 
Measure  
Assessed with: LS mean change from baseline  
167 






-  -  
MD - 6.3 
points 
(-8.81 to - 
3.79)  
Symptoms of anxiety and depression Hospital 
Anxiety and Depression Scale (HADS)  
Assessed with the LS mean change from 
baseline 
167 











Quality of life measured by Children’s 
Dermatology Life Quality Index (CDLQI) 
Assessed with LS mean change from baseline 
167 






-  -  
MD -13.6 
points  
(-15.13 to - 
12.07)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).  
 
AE= adverse events; CI: Confidence interval; LS = least square; MD: Mean difference; MID: minimal important difference 
RR: Risk ratio; SAE = serious adverse events 
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderately confidence in the effect estimate: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate : the true effect may be substantially different from the estimate of the 
effect 
Very low certainty: Very limited confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect 
References 
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Severe Atopic Dermatitis: a Phase 3 Randomized Clinical Trial. JAMA dermatology; 2019. 156(2):131-143. 
 
Explanations 
a. The MID for SCORAD is 8.7 points (European Task Force 1993).  
b. Included studies were funded by industry. No industry-independent observational or randomized studies were identified 
to contrast the results. No industry-independent observational or randomized studies were found to support these results 
(sponsorship industry bias was assessed as other bias as part of the ROB tool). The panel members considered that there 
were no major concerns about potential publication/sponsorship bias 
c. The MID for EASI is 6.6 points  
d. The clinically improvement cut off for NRS was considered as 4   











f. The clinically relevant end point outcome was considered as the proportion of the patients with HADS-A and HADS-D 
scores <8   
g. The effect may be harmful or beneficial  
h. The MID for CDLQI is 6 points  











Table 5 A: Summary of evidence for the economic impact of dupilumab in addition to standard care 
(emollients) vs. standard of care 





















































*Incremental cost and effect due to the addition of dupilumab (not reported by the CADTH study). ICER: Incremental cost-
effectiveness ratio. QALY: Quality adjusted life years. USD$: US Dollar. 
Explanations 
a. Markov model studies with low risk of bias (CHEC score 13 or higher).  
b. The studies were performed in the USA and Canada. The results may not be applicable to other countries. 
c. The sensitivity analyses of the US studies showed variations in the ICER value from 78,300 USD$ in patients with 
severe AD and 159,988 USD$ in moderate AD. At a threshold of 150,000 USD$, the probability for dupilumab to be 
cost-effective was 77% or higher in all three studies. CADTH undertook a scenario analysis for patients who are 
refractory to or ineligible for systemic immunosuppressant therapies, which resulted in an ICER of $133,877 Canadian 
Dollars, that is included in the ICERs found by the US studies.  
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Table 5 B: Summary of evidence for the economical impact of Dupilumab in addition to topical corticoids (as 
fifth-line treatment, after systemic immunosuppressant therapies) vs. best supportive care (education, 
psychological support, emollients, topical corticosteroids, bandages and hospitalisation) 














































*Incremental cost and effect due to the addition of dupilumab. ICER: Incremental cost-effectiveness ratio. QALY: Quality 
adjusted life years. £: British Pounds. 
Explanations 











b. Very serious indirectness due to differences in the comparator and the population. First, the comparator was best 
supportive care (include education, psychological support, emollients, topical corticosteroids, bandages and 
hospitalisation), which is different to the standard care that included topical treatments. Second, the study was 
performed in the UK for patients that could receive dupilumab as fifth-line treatment, after systemic 
immunosuppressant therapies. The results may not be applicable to other populations. 
c. The sensitivity analysis that use a curve fit estimator of maintenance of response of 18.2%, 10.3%, 6.2% and 3.7% in 
the best supportive care arm showed an ICER of £27,410. 
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